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Electroporation-mediated HGF gene transfer ameliorated cy-
closporine nephrotoxicity.
Background. The clinical utility of cyclosporine A (CsA) has
been limited by its nephrotoxicity, which is characterized by
tubular atrophy, interstitial fibrosis, and progressive renal im-
pairment. Hepatocyte growth factor (HGF) has been reported
to protect and salvage from renal injury as a renotropic and
antifibrotic factor. Here, we investigated protective effects of
HGF gene therapy on rat CsA-induced nephrotoxicity using
electroporation-mediated gene transfer.
Method. CsA was subcutaneously administered daily under
low sodium diet, and HGF gene was transferred into skeletal
muscle by electroporation on days 7 and 14. We also examined
the antiapoptotic mechanism of HGF using human proximal
tubular epitherial cells.
Results. HGF gene transfer rescued CsA-induced initial
tubular injury and suppressed interstitial infiltration of ED-1–
positive macrophages in CsA-induced nephrotoxicity. In ad-
dition, HGF significantly inhibited tubular cell apoptosis, and
increased the number of proliferating tubular epithelial cells.
In vitro studies suggest that HGF executes the antiapoptotic
function by enhancing the phosphorylation of Akt and Bcl-2.
Northern blot analysis demonstrated that HGF gene transfer
suppressed cortical mRNA levels of transforming growth factor-
b (TGF-b). Consequently, HGF gene transfer significantly re-
duced a striped interstitial phenotypic alteration and fibrosis.
Conclusion. We demonstrated that HGF gene transfer
reduced CsA-induced tubular cell apoptosis and interstitial fi-
brosis. HGF gene transfer could be a potential strategy for pre-
venting renal fibrosis.
The introduction of cyclosporine (CsA) into clinical
practice has resulted in marked improvement in the short-
term outcome of organ transplantation, and 1-year sur-
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vival of renal allografts has improved significantly [1, 2].
However, the dose-limiting adverse effect of long-term
CsA administration is chronic nephrotoxicity, which re-
mains as an unsolved problem of transplant therapy and
limits clinical utility of CsA [1, 3]. Chronic CsA nephro-
toxicity may progress to an irreversible renal lesion char-
acterized by tubular atrophy, striped interstitial fibrosis,
hyalinosis of the afferent arteriole, and progressive re-
nal impairment [4, 5]. While acute CsA nephrotoxicity
is thought to be a result from intrarenal vasoconstric-
tion, the mechanism leading to the interstitial fibrosis of
chronic CsA nephrotoxicity remains unclear. Previous re-
sults showed tubular epithelial cells underwent apopto-
sis in the course of immunosuppression with CsA [6]. In
addition, CsA-induced nephrotoxicity is associated with
up-regulation of transforming growth factor-b (TGF-b1),
type I collagen, and TGF-b1 is considerably important to
its progression [7].
Hepatocyte growth factor (HGF), a multifunctional
polypeptide originally characterized as a potent mito-
gen for mature hepatocyte in primary culture, is a het-
erodimeric molecule consisting of a 69 kD a chain and
a 34 kD b chain held together by a disulfide bond [8, 9].
HGF and its specific c-met receptor constitute a signaling
system that plays an important role in renal development
and in the maintenance of normal adult kidney struc-
ture and functions. HGF elicits potent mitogenic, moto-
genic, morphogenic, and antiapoptotic activities in renal
tubular epitherial cells. Recent studies reports that HGF
has numerous functions in diverse cell survival and tissue
regeneration [10]. Administration of cisplatin caused
acute renal failure in mice, while HGF administration
prevented histologic destruction of renal tubules and
strongly suppressed the onset of acute renal dysfunction
[11]. Likewise, HGF-treated rats showed a lesser degree
of histologic injury when renal ischemia was induced by
arterial occlusion [12]. HGF has been also suggested to
act as a cell survival factor by inhibiting apoptosis in
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various cells. In addition to protective or regenerating
effect of HGF on tubular epithelial cells [13], HGF
has been reported to have antifibrotic effects [14]. Ad-
ministration of exogenous HGF protein effectively in-
hibits the activation of matrix-producing myofibroblasts,
attenuates extracellular matrix deposition and intersti-
tial fibrosis, and by suppressing profibrogenic cytokine
TGF-b1 and its type I receptor expression in vivo. These
observations suggest that exogenous HGF supplementa-
tion has a therapeutic role in the development of CsA-
induced nephrotoxicity.
However, it is difficult to sustain a level of exogenous
HGF in vivo by intravenous repeated injection of puri-
fied protein even at very short intervals, because exoge-
nous HGF is very unstable in blood circulation due to
the rapid clearance by the liver [15]. In this point of view,
repeated injections of recombinant HGF protein are
both inconvenient and extremely costly. To circumvent
this problem, we developed a new gene transfer system
by electroporation in vivo. Recently, we demonstrated
that PDGF receptor-IgG Fc chimera (PDGFR/Fc) gene
transfer by electroporation to rat muscle resulted in in-
creased plasma concentration of PDGFR/Fc molecule
and thereby ameliorated the disease progression in ex-
perimental glomerulonephritis [16]. Electroporation is
free from oncogenicity, immunogenicity, and cytotoxic-
ity of viral vectors. In addition, electroporation-mediated
gene transfer technique showed significantly higher trans-
fection efficiency than hemagglutinating virus of Japan
(HVJ) liposome method [17]. In the present study, we
investigated the effects of HGF gene transfer into CsA-
induced nephrotoxicity in rat. This gene transfer ap-
proach may provide an efficient way to investigate the
therapeutic potential of HGF gene transfer for long-term
survival of allograft kidney.
METHODS
Cell culture and treatment
Human proximal tubular epithelial HK-2 cells
(American Type Culture Collection; Manassas, VA,
USA) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)/F-12 medium (Gibco Laboratories,
Grand Island, NY, USA) supplemented with 5% fetal
bovine serum (FBS) Gibco Laboratories) and piperaci-
line/streptomysin (Sigma Chemical Co., St. Louis, MO,
USA) at 37◦C in a humidified atmosphere of 5% CO2
and 95% air atmosphere. Cells were seeded at 3 × 105 per
60 mm culture disk in growth medium for 24 hours before
pharmacologic treatment. To examine the effect of HGF
on CsA-induced apoptosis, human recombinant HGF
(50 ng/mL) was added to the culture medium. One hour
after HGF treatment, culture medium was replaced with
40 lmol/L of CsA dissolved in 0.1% of dimethyl sulfoxide
(DMSO) and cells were incubated for 24 hours. DMSO
alone was used as a control. In some experiments, cells
were pretreated with 50 lmol/L of zVAD-fmk (Promega,
Madison, WI, USA), a caspase inhibitor, for 1 hour be-
fore CsA treatment.
Caspase-3 activity assay
Caspase-3 protease activity was assayed by following
the manufacturer’s instructions (Promega). Shortly, HK-
2 cells were washed twice with phosphate-buffered saline
(PBS) and carefully collected. The cell pellets were sus-
pended in the cell lysis buffer containing 25 mmol/L
HEPES (pH 7.5), 5 mmol/L MgCl2, 5 mmol/L ethylene-
diaminetetraacetic acid (EDTA), 5 mmol/L dithiothre-
itol (DTT), 2 mmol/L phenylmethylsulfonyl fluoride
(PMSF), 10 lg/mL pepstatin A, and 10 lg/mL leu-
peptin, and the cells were lysed by freeze and thaw-
ing for three times. The homogenates were cleared by
centrifugation at 15000g, 4◦C for 20 minutes. The cen-
trifugation step was repeated and the clear supernatants
were used for the caspase assay. After determination
of the protein concentration using bovine calf albu-
min (BCA), caspase-3 activity was measured by mix-
ing 54 lL of equivalent extract, 32 lL of caspase assay
buffer containing 312.5 mmol/L HEPES, pH 7.5, 31.25%
wt/vol sucrose, 0.3125% wt/vol 3-[(3-cholamido-propyl)
dimethylammonio]-1-propanesulfonate (CHAPS), 10 lL
of 100 mmol/L DTT, 2 lL DMSO, and 2 lL colorimet-
ric substrate (10 mmol/L Ac-DEVD-pNA in DMSO).
Free pNA released from the substrate upon cleavage by
DEVEase, producing yellow color, was measured by a
photometer at 405 nm. From the data, specific caspase-3
activities were calculated using pNA calibration curves.
Western blot analysis
To examine the antiapoptotic mechanism of HGF on
CsA cytotoxicity, cells were treated with 40 lmol/L of
CsA and/or 50 ng/mL of human HGF as above. There-
after, cells were washed with PBS and lysed in cell lysis
buffer (Cell Signaling, Beverly, MA, USA). Cell lysates
were centrifuged for 15 minutes at 4◦C to remove debris,
and the protein concentrations were determined using
BCA method. The lysates (20 lg) were applied into sam-
ple buffer [58.3 mmol/L Tris, pH 6.8, 2% sodium dodecyl
sulfate (SDS), and50 mmol/L DTT, melcaputoethanol,
and bromophenol blue] and subjected to 10% SDS-
polyacrylamide gel electrophoresis (PAGE), and elec-
trotransferred to polyvinylidene difluoride (PVDF)
(Hybond P; Amersham Corp., Buckinghamshire, UK).
Immunoblotting was performed with appropriate anti-
bodies; anti-Akt antibody (Cell Signaling), anti-phospho
Akt antibody (Cell Signaling), and antirat bcl-2 antibody
(MBL, Watertown, MA, USA).
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Experimental design
To examine the efficiency of HGF gene transfer on
CsA nephrotoxicity, 6-week-old male Sprague-Dawley
rats (SLC Japan, Hamamatsu, Japan) weighing 180 to
190 g received daily subcutaneous injections of CsA at
30 mg/kg dissolved in 100 lL of sesame oil under low-salt
diet (0.03% sodium) (Test Diet, Richmond, IN, USA).
On day 7 or 14, rats were anesthetized by an intraperi-
toneal injection of pentobarbital (50 mg/kg) and tibialis
anterior muscles, which were pretreated with 50 lg of
bupivacaine, were exposed. We previously reported that
pretreatmemt of bupivacaine combined with electropo-
ration significantly enhanced the gene expression of the
transfected muscle [16]. Thereafter, 100 lL of PBS con-
taining pCAGGS-HGF (200 lg) (CsA/HGF group) or ve-
hicle (CsA group) was transfected by electroporation into
the bupivacaine-treated muscle as previously reported
(N = 12 in each group) [16]. Plasmid DNA pCAGGS-
HGF was constructed by inserting the XbaI-BamHI
fragment containing full length cDNA of rat HGF
into pUC-CAGGS, which contains the cytomegalovirus
enhancer and b-chicken promoter. Shortly, a pair of
tweezers-type electrodes was inserted into the tibialis an-
terior muscle to encompass the DNA injection sites, and
the square wave of electric pulses was delivered. Three
pulses of 75 V each, lasting 100 milliseconds, and three
pulses of opposite polarity were applied. On day 14 or
21, plasma samples were collected and kidneys were re-
moved after perfusion with 20 mL of cold PBS. The cor-
tex was carefully dissected from medulla and was then
processed for evaluation by light microscopy, RNA anal-
ysis, and immunohistochemistry. Plasma was harvested
immediately by centrifugation at 4◦C and stored at −80◦C
until determined. Plasma HGF concentration was mea-
sured by enzyme immunogen assay method (Institute of
Immunology, Tokyo, Japan). To investigate the effect of
HGF gene transfer on normal kidney, we also transfected
the HGF gene into the muscle of normal rat and harvested
(N = 3 in each time point).
Analysis of plasma samples
Serum creatinine and urea nitrogen levels were mea-
sured by creatinase-peroxydase method and urease-
ultravioltet method, respectively (SRL, Inc., Osaka,
Japan). The blood level of CsA was measured by a mon-
oclonal radioimmunoassay for CsA (SRL, Inc.). Plasma
HGF concentration was measured by enzyme immuno-
gen assay (EIA) method (Institute of Immunology).
Histologic examination
Tissue samples were fixed in 4% buffered
paraformaldehyde for 12 hours and embedded in
paraffin. Histologic sections (2 lm) were stained with
periodic acid-Schiff (PAS) and Masson’s trichrome.
Tubulointerstitial injury was evaluated on PAS-stained
sections by lesions, including tubular casts, dilation and
atrophy, thickening of tubular basement membrane, and
interstitial matrix expansion. The interstitial fibrotic area
was stained blue in Masson’s trichrome staining, and
color image analyzer estimated the area quantitatively.
The percentage of fibrotic areas per field of cortex was
counted at ×400 magnification in the minimum of 10
fields [18].
Immunohistochemical stainings
Renal tissues were also fixed in cold methyl Carnoy’s
solution for 6 hours and exchanged into cold 70% ethanol,
and then embedded in paraffin in a routine fashion. Tissue
sections were cut at a thickness of 4 lm and were dewaxed
and stained with ED-1 antibody to identify macrophage
infiltration, followed by a second reaction with biotin-
labeled antirat IgG antibody (Vector, Burlingame, CA,
USA). Finally, an avidin-biotin coupling (ABC) reac-
tion was performed on the sections (Vectastain Elite)
(Vector). To stain a-smooth muscle actin (a-SMA), a
marker of interstitial myofibroblasts, anti-a-SMA mon-
oclonal antibody (EPOS System) (Dako A/S, Glostrup,
Denmark) was used. In order to monitoring of the pro-
liferation of tubulointerstitial cells, we used anti Ki-67
antibody (Dako A/S).
TUNEL assay
DNA fragmentation associated with apoptosis was
detected in situ in tissue sections by the addition
of fluoresceine-labeled nucleotides to free 3′hydroxyl
groups in DNA by the terminal deoxynucleotidyl
transferase (TdT)-mediated deoxyuridine triphosphate
(dUTP) nick end labeling (TUNEL) method using In Situ
Apoptosis Detection Kit (TaKaRa Biomedicals, Tokyo,
Japan). Sections were dewaxed and treated with pro-
teinase K (400 lg/mL) for 5 minutes at room temperature
and incubated with 3% H2O2 for 20 minutes at room tem-
perature to inactivate endogenous peroxidase. Sections
were rinsed with PBS three times for 5 minutes, then im-
mersed in Labeling Safe buffer (TaKaRa Biomedicals)
with TdT enzyme (TaKaRa Biomedicals) at 37◦C for 60
minutes. Sections were washed by PBS and incubated
with anti-fluorescein isothiocyanate (FITC) horseradish
peroxidase (HRP) conjugate at 37◦C for 30 minutes.
Apoptotic nuclei were visualized by the addition of di-
aminobenzidine and counterstained with methyl green.
TUNEL-positive cells were counted in the cortical tubu-
lar cells at ×200 magnification in the minimum of 10 fields.
Semiquantitation of phenotypic alteration
The area of the fibrotic lesion of cortical interstitium
was determined in sections stained by Masson’s trichrome
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method to stain collagen fibers (in light blue) in the inter-
stitial space. Under high-power magnification (×400), 10
nonoverlapping fields from the cortical region were se-
lected at random and analyzed by an observer unaware
of the experimental protocol. The fibrotic areas in the
interstitium were highlighted on digitized images using
a computer-aided manipulator (microscope) (Leitz DM
IRB, software) (Quantimet 500+) (Leica, Tokyo, Japan).
The fibrotic area relative to the total area of the field
was calculated as a percentage. Glomeruli and large ves-
sels were not included in the microscopic fields for image
analysis. The scores of 10 fields per kidney were averaged,
after which the mean scores from 12 separate animals per
group were averaged.
Northern blot analysis
Renal tissue was finely minced with an autoclaved
blade and immediately immersed in liquid nitrogen,
and then homogenized in TRIzol reagent (Gibco BRL).
RNA extraction was performed according to the man-
ufacturer’s protocol. After resuspension in Tris-EDTA
buffer, 15 lg of RNA were electrophoresed in each
lane in 1% agarose gels containing 2.2 mol/L formalde-
hyde and 0.2 mol/L 3-[N-morpholino] propane sulfonic
acid (MOPS) (pH 7.0) and were transferred to a nylon
membrane (Hybond N) (Amersham). The membranes
were prehybridized for 1 hour at 42◦C with 50% for-
mamide, 10% Denhardt’s solution, 0.1% sodium phos-
phate, 5 × standard saline citrate (SSC), and 180 mg/mL
denatured salmon sperm DNA. They were hybridized
at 42◦C for overnight with cDNA probes labeled with
32P-dexoycytidimine triphosphate (dCTP) by random
oligonucleotide priming (RediPrime, Burlingame, CA,
USA). The blots were washed in 2 × SSC, 0.1% SDS
at room temperature two times for 15 minutes and in
0.2 × SSC, 0.1% SDS at 60◦C two times for 10 minutes.
Films were exposed at −80◦C for approximately 24 hours.
The density of bands for glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) mRNA was used to control for
differences in total amount of RNA loaded onto each gel
line.
Statistical analysis
All values are expressed as means ± SD. Statistical
significance (defined as P < 0.01) was evaluated using
the one-way analysis of variance (ANOVA).
RESULTS
Physiologic studies
Serum creatinine and urea nitrogen levels at the end of
study were summarized in Table 1. In comparison of nor-
mal control group (serum creatinine 0.23 ± 0.04 mg/dL
and urea nitrogen 24.0 ± 2.30 mg/dL), serum creatinine
Table 1. The final concentration of serum creatinine, urea nitrogen,
cyclosporine A (CsA) whole blood level, and plasma hepatocyte
growth factor (HGF) in each group
Serum Urea CsA whole Plasma
creatinine nitrogen blood level HGF
Groups mg/dL mg/dL ng/mL ng/mL
CsA day 14 0.34 ± 0.06 33.5 ± 7.8 3667 ± 416 1.249 ± 0.138
HGF day 14 0.28 ± 0.03 25.1 ± 2.9 3200 ± 436 1.681 ± 0.076
CsA day 21 0.48 ± 0.07 54.2 ± 13.5 4275 ± 608 1.229 ± 0.076a
HGF day 21 0.46 ± 0.07 53.6 ± 5.8 4050 ± 420 1.578 ± 0.332
aP < 0.05 vs. CsA day 14.
and urea nitrogen gave a significant rise in both CsA
group and CsA/HGF group (P < 0.05 vs. normal con-
trol group). However, creatinine and urea nitrogen lev-
els were higher in CsA group compared with CsA/HGF
group (not significant, P = 0.19).
Plasma concentration of HGF was measured by EIA
method. In normal control rats, plasma concentration
of HGF increased to 4.88 ± 0.75 ng/mL at day 3 after
HGF gene transfection, and declined, reaching 0.96 ±
0.87 ng/mL and 0.47 ± 0.36 ng/mL at day 5 and day
14, respectively. Northern analysis of muscle treated with
HGF gene showed that HGF mRNA expression persisted
14 days after transfection (data not shown). CsA adminis-
tration increased plasma HGF levels (1.25 ± 0.14 ng/mL
and 1.23 ± 0.08 ng/mL at 2 and 3 weeks, respectively);
however, HGF gene transfer attained further up-rise of
plasma HGF level (1.69 ± 0.08 ng/mL and 1.59 ± 0.32 ng/
mL at 2 and 3 weeks, respectively).
Effect of HGF gene transfer on tubulointerstitial injury
PAS staining revealed that CsA treatment induced
characteristic histologic changes by 2 weeks, including
tubular atrophy and dilation, early striped fibrosis, and
inflammatory cell infiltration. By 3 weeks, these lesions
were more prominent and extensive with severe intersti-
tial fibrosis (Fig. 1A). In addition, arteriolar hyalinosis
was observed in CsA group (black arrow). However,
HGF gene transfer alleviated these tubulointerstitial in-
juries (Fig. 1B), and ameliorated arteriolar hyalinosis
(white arrow).
The degree of interstitial fibrosis was quantitatively as-
sessed as fibrotic fractional volume of renal cortex using
a computer-aided manipulator on Masson’s trichrome–
stained sections (Figs. 1C and D and 2A). CsA group
showed progression of interstitial fibrosis with 5.54 ±
1.46% and 6.69 ± 1.32% at 2 and 3 weeks of CsA
treatment, respectively. In parallel with the findings on
tubulointerstitial injury, HGF gene transfer significantly
suppressed the development of interstitial fibrosis at 2
and 3 weeks (3.86 ± 0.89% and 4.99 ± 1.46% at 2 and
3 weeks, respectively, P < 0.01 vs. CsA group).
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Fig. 1. Renal histopathology and immunohistochemistry. Representative photomicrographs showed the renal morphologic changes of periodic
acid-Schiff (PAS) (A and B) and Masson’s trichrome (C and D) staining, immunohistchemistry of alpha-smooth muscle actin (a-SMA (E and F)
and ED-1 (G and H) in cyclosporine A (CsA) group (A, C, E, and G) and CsA/hepatocyte growth factor (HGF) group (B, D, G, and H) at day 21.
Arteriolar hyalinosis was observed in CsA group (A, black arrow); however, HGF gene transfer ameliorated arteriolar hyalinosis (B, white arrow).
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Fig. 2. Semiquantification of histologic
changes. The fractional volume of interstitial
fibrotic area (A) and alpha-smooth muscle
actin (a-SMA–positive area (B) in the cortex
(excluding glomeruli) was estimated at the
field of ×400 in the minimum of 10 fields by
computer-aided manipulator. ED-1–positive
cells were counted at ×200 in the minimum
of 10 fields (C). Symbols are: () cyclosporine
(CsA groups); () CsA/hepatocyte growth
factor (HGF) groups. Data are expressed as
mean ± SD. ∗P < 0.01; ∗∗P < 0.001; #P <
0.0001, CsA treated group compared with
CsA/HGF group.
Phenotypic alteration and macrophage infiltration
Phenotypic alteration into myofibroblast, which was
estimated by immunohistochemical staining of a-SMA,
leads to extracellular matrix accumulation. Upon 2 weeks
treatment of CsA, a significant increase was noted in a-
SMA, followed by a further increase by 3 weeks (4.86 ±
0.97% and 5.66 ± 1.67%, respectively) (Figs. 1E and 2B).
Expression of a-SMA occurred in the areas of tubu-
lointerstitial fibrosis, with most pronounced increases
seen around the thickened basement membrane of the
Bowman’s capsule and degenerated tubules. However,
progressive expression of a-SMA was significantly sup-
pressed by the intervention with HGF gene transfer at
2 and 3 weeks (2.76 ± 1.09% and 3.71 ± 1.27%, respec-
tively, P < 0.0001 vs. CsA group) (Figs. 1F and 2B).
CsA treatment induced marked and continuous infil-
tration of ED-1–positive macrophages throughout the
experiment. Accumulation of ED-1–positive cells was
observed around the damaged tubules and within the
interstitium (Fig. 1G). The number of macrophages in-
creased persistently in CsA group at 2 and 3 weeks
(59.43 ± 15.15 cells per high power field and 70.53 ±
15.66 cells per high power field, respectively) (Fig. 2C).
In contrast, macrophage accumulation was significantly
repressed in CsA/HGF group both at 2 and 3 weeks
(32.00 ± 8.70 and 45.23 ± 10.88 positive cells per high-
power fields, respectively, P < 0.001 vs. CsA group) (Figs.
1H and 2C).
Renal tubular cell proliferation by HGF gene transfer
Ki-67 antigen is a large nuclear protein preferentially
expressed during active phase of the cell cycle (G1, S, G2,
and M phases), but absent in resting cells (G0) and its
antibody is valuable by allowing direct monitoring of the
growth fraction of normal and neoplastic cells. To assess
the regeneration of tubular epithelial cells, cortical Ki-67–
positive tubular cells were counted at ×200 magnification
in the minimum of 10 fields. Ki-67–positive cells were few
in normal kidney (1.00 ± 1.17) (Fig. 3A), but significantly
increased in CsA group at 2 weeks and 3 weeks (6.54 ±
2.11 and 6.31 ± 2.55, respectively, P < 0.0001 vs. nor-
mal control) (Fig. 3B and D). HGF gene transfer showed
further increased Ki-67–positive cells (8.92 ± 2.43 at 2
weeks, P = 0.006, and 10.41 ± 3.48 at 3 weeks, P < 0.0001
vs CsA group) (Fig. 3C and D). Of interest is that Ki-
67–positive cells existed mainly in damaged interstitial
lesions in CsA-treated kidney (Fig. 3B, left area), while
Ki-67–positive cells were observed in tubular epithelial
cells, but not in interstitium in HGF group.
Morphologic evidence of apoptosis
To investigate whether HGF gene transfection could
protect the tubular apoptosis, we examined the apop-
totic bodies, marked as an in situ end-labeled DNA frag-
ment with the TUNEL method. In parallel with the tubu-
lointerstitial damage, tubular apoptosis was persistently
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Fig. 3. Renal tubular cell proliferation. Representative photographs showed immunohistochemical staining of Ki-67 antigen, a cell proliferation
marker, in normal kidney (A), cyclosporine A (CsA) group (B), and CsA/hepatocyte growth factor (HGF) group (C). Ki-67–positive renal tubular
cells also increased in CsA treatment group, but further increase was shown in CsA/HGF group. Proliferative cells were mainly observed in damaged
interstitial lesions in CsA-treated kidney (B, arrow). Ki-67–positive cells were counted at ×200 in the minimum of 10 fields at day 14 and 21 (D).
Symbols are: () CsA groups; () CsA/HGF groups. Data are expressed as mean ± SD. ∗P < 0.01; #P < 0.001.
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Fig. 4. Apoptosis detected bv terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling
(TUNEL) assay. TUNEL-positive cells (green arrows) were often detected in the cortical area in cyclosporine A (CsA) administration for 3
weeks (A), and these were suppressed by hepatocyte growth factor (HGF) gene transfer (B). The scores of TUNEL positive cells were counted
in the cortical tubular cells at ×200 magnification in the minimum of 10 fields at day 14 and 21 (C). Symbols are: () CsA groups; () CsA/HGF
groups. Data are expressed as mean ± SD. ∗P < 0.001.
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Fig. 5. Immunohistochemical staining of phosphorylated Bad. In normal kidneys, the phosphorylated-Bad was not detectable by immunohis-
tochemstry. After the induction of cyclosporine A (CsA) treatment, obvious but weak phosphorylated Bad staining was present (A). In hepatocyte
growth factor (HGF)-treated kidney phsophorylated Bad was abundantly up-regulated (B).
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Fig. 6. Changes of caspase-3 activity. HK-2 cells were treated with cy-
closporine (CsA) (40 lmol/L) for 24 hours with or without hepatocyte
growth factor (HGF) (50 ng/mL) pretreatment for 1 hour. Experiments
were performed in ternary. Caspase-specific activity was calculated by
constructing of pNA (p-nitroaniline) caliblation curve and applying the
value of absorbance OD405. The number of Y axis represents pmol
pNA liberated per hour/lg protein. Data are expressed as mean ± SD.
∗P < 0.005 CsA group compared with control group; ∗∗P < 0.01 CsA/
HGF group compared with CsA group. DMSO is dimethyl sulfoxide.
increased at 2 and 3 weeks after CsA treatment (3.45 and
5.25 cells per high power field, respectively) (Fig. 4A and
C), while HGF significantly inhibited tubular apoptosis
(1.2 and 2.65 cells per high power field, respectively, P <
0.001 vs. CsA group) (Fig. 4B).
As we determined that HGF gene therapy could
successfully inhibit apoptosis in CsA-induced tubu-
lointerstitial injury, we examined the possible mecha-
nism of apoptosis by staining the phosphorylated-Bad
expression. Bad promotes apoptosis in part through
heterodimerization with the survival proteins Bcl-2 and
Bcl-xL. Phosphorylation of Bad prevents this apopto-
sis. In normal kidneys, the phosphorylated-Bad was not
detectable by immunohistochemstry. After the induc-
tion of CsA treatment, obvious but weak phosphorylated
Bad staining was present (Fig. 5A). In HGF-treated kid-
ney phsophorylated Bad was abundantly up-regulated
(Fig. 5B).
Caspase-3 activity assay in HK-2 cells
In order to provide direct evidence for caspase activa-
tion, we investigated the activity of caspase-3 in human
proximal tubular epitherial (HK-2) cells. Caspase-3 ac-
tivity was up-regulated only under the exposure of 0.1%
DMSO (3.98 ± 0.11) as the control group, and showed sig-
nificant increase by CsA treatment (7.44 ± 0.39, P < 0.005
vs. control). However, HGF pretreatment significantly in-
hibited the CsA-induced up-regulation of caspase-3 ac-
tivity (5.10 ± 0.49, P < 0.01 vs. CsA group) (Fig. 6).
Western immunoblot analysis on HK-2 cells
To demonstrate the mechanism of apoptosis inhibi-
tion by HGF, we performed Western immunoblot anal-
ysis of phosphorylated-Akt, Bcl-2, and Bax proteins
(Fig. 7A). Western blot analysis showed that CsA treat-
ment reduced Bcl-2 protein level to 0.57 ± 0.10 of that
in untreated HK-2 cells. However, additional treatment
with HGF recovered the expression of Bcl-2 protein to
0.97 ± 0.19 of that in untreated HK-2 cells (Fig. 7B). In ad-
dition, the treatment of HGF significantly increased the
phosphorylation of Akt in CsA-treated cultured cells (the
relative ratio of phosphorylated Akt signals to Akt signals
4.27 ± 0.11 × 10−2 in HGF/CsA vs. 2.78 ± 0.39 × 10−2 in
CsA, P < 0.05) (Fig. 7C). Neither CsA nor HGF affected
Bax expression (data not shown). Total Akt protein levels
were similar in all groups. However, Akt phosphrylation,
an active form of Akt, was suppressed by CsA, but was
increased by HGF.
Northern blot
Northern analysis was performed of renal cortex in
each of four groups. The cortical mRNA expression of
TGF-b was up-regulated in CsA group by day 14 com-
pared with normal control group, while HGF treatment
significantly reduced TGF-b mRNA expression (ratios
of TGF-b signal to GAPDH signal 0.168 ± 0.007 in CsA
group vs. 0.091 ± 0.002 in CsA/HGF group, P < 0.01).
The inhibitory effect on TGF-b was also observed at day
21.
DISCUSSION
In the present study, we found that HGF gene
transfer into muscle using electroporation had a pro-
tective effect on chronic CsA-induced nephrotoxicity.
Here, we demonstrated that HGF gene transfer reduced
CsA-induced tubulointerstitial injury. Tubular epithelial
apoptosis was suppressed and macrophage infiltration,
phenotypic alteration of interstitial myofibroblasts, and
interstitial fibrosis were also restricted in HGF group.
Several reports indicated the involvement of HGF
in renal regeneration [10, 19]. Rapid increases in HGF
mRNA and/or protein levels in the kidney and plasma
were observed in various types of renal injury induced
by nephrotoxins, renal ischemia, and ureteral obstruc-
tion [10]. Recently, it has been reported that endogenous
as well as exogenous HGF prevents renal fibrosis in a
mouse model of nephritic syndrome [20]. The present
study obtained three major findings: (1) exogenous sup-
ply of HGF provided effective protection from tubular
apoptosis caused by CsA treatment in vitro and in vivo;
(2) HGF gene transfer induced tubular cell proliferation;
and (3) HGF gene transfection suppressed the expres-
sion of TGF-b followed by the inhibition of interstitial
fibrosis.
We showed the therapeutic effects of HGF transgene
approach on CsA-induced tubular epithelial injury. PAS
staining revealed that CsA treatment induced tubular
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Fig. 7. The protective mechanism of hepato-
cyte growth factor (HGF) from apoptosis in
HK-2 cells. (A) Western immunoblot of HK-2
cells for the treatment of 0.1% dimethy sulfox-
ide (DMSO) used as control (left), 40 mmol/L
cyclosporine A (CsA) in 0.1% DMSO for
24 hours (middle), 40 mmol/L CsA in 0.1%
DMSO for 24 hours before 1-hour treatment
of 50 ng/mL HGF (right). Graphic presenta-
tions represent quantitative abundance of bcl-
2 expression levels (B) and phospho-Akt/Akt
ratio (C).
atrophy and dilatation; however, HGF gene transfer ame-
liorated these observations. In parallel with the tubular
injury, tubular apoptosis was persistently increased at 2
and 3 weeks after CsA treatment, while HGF significantly
inhibited tubular apoptosis. In addition, Ki-67 staining
showed that HGF gene transfer significantly increased
the number of proliferating tubular epithelial cells. Of
interest is that HGF treatment did not accelerate the
proliferation of interstitial myofibroblasts, while Ki-67–
positive cells were likely to be limited to damaged inter-
stitial lesion of CsA-treated kidney. To address whether
HGF gene transfer affects normal kidney, we transferred
HGF gene into the muscle of normal rats. We observed no
histologic changes (tubular apoptosis or interstitial infil-
tration) in HGF gene-treated normal kidney. However,
cortical Ki-67–positive tubular epithelial cells were sig-
nificantly increased on day 3 and sustained until day 14
(Fig. 9). This observation supports the previous report
that HGF promotes DNA synthesis of tubular epithelial
cells [21]. These results emphasized the protective effect
of HGF gene transfer on the balance of tubular cell prolif-
eration and apoptosis in CsA-induced tubulointerstitial
injury.
In this study, we also showed that HGF supplementa-
tion inhibited CsA-induced arteriolar hyalinosis. Arteri-
olar hyalinosis induced by CsA is a well-described but
poorly characterized lesion. Although it has been com-
monly known that the chronic form of CsA injury is a con-
sequence of CsA-induced arteriolar vasoconstriction of
vascular smooth muscle cells, the development of arterio-
lar hyalinosis may be due to direct toxicity of CsA, rather
than a hemodynamic consequence. The precise mecha-
nism why HGF gene transfer suppressed arteriolar hyali-
nosis remains unclear in this study. However, we observed
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Fig. 8. Northern analysis of renal cortex.
Northern analysis showed the representa-
tive cortical mRNA levels of transforming
growth factor-b (TGF-b) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) in
normal control kidney and cyclosporine A
(CsA)-treated and hepatocyte growth factor
(HGF) gene-transferred rats at days 14 and
21.
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Fig. 9. Effect of hepatocyte growth factor (HGF) gene transfer in nor-
mal rat kidney: Cortical Ki-67–positive tubular epithelial cells were
counted for the time course. Ki-67–positive cells were significantly in-
creased at 3 days after HGF gene transfer and sustained until day 14.
#P < 0.001 vs. normal group.
no changes in systemic blood pressure after HGF gene
transfer. Therefore, suppression of arteriolar hyalinosis
is not due to the direct influence of systemic hemody-
namics. However, it is possible that HGF may affect the
renal hemodynamics via the escape from tubular apopto-
sis and interstitial fibrosis. The recent study demonstrates
that low CsA doses generated interstitial fibrosis with ar-
teriolar hyalinosis, possibly through macrophage infiltra-
tion and increased TGF-b expression [22]. In addition,
it was reported that local HGF secretion from vascular
cells was negatively regulated by TGF-b [23]. Accord-
ing to this notion, the supplementation of HGF inhibited
the arteriolar hyalynosis and improved renal blood flow,
thereby protecting tubular cells from ischemic injury.
Another mechanism of the suppression in tubulointer-
stitial injury may be associated with anti-apoptotic effect
of HGF on renal epithelial cells, which is partly medi-
ated by the induction of the phosphorylation of Akt. We
demonstrated that HGF supplementation induced the
phosphorylation of Akt in vitro tubular epithelial cells.
Activation of Akt has been shown to protect a wide va-
riety of cells from apoptosis. It is reported that Akt is
rapidly activated during liver regeneration and that acti-
vation of Akt protects hepatocyte from TGF-b–induced
apoptosis in vitro [24]. Several downstream targets of
Akt (such as E2F, c-myc, and Bad) have been implicated
in cell cycle progression and antiapoptosis [25]. Among
these, the phosphorylation of Bad and its consequent
dissociation from Bcl-xL is the most important signal-
ing event linked to the anti-apoptotic effect of Akt [26].
Treatment of tubular epithelial cells with CsA inactivated
Akt, while HGF treatment recovered them from its inac-
tivation. We further examined the effect of HGF on the
phosphorylation of Bad in CsA-treated kidney. Immuno-
histochemistry revealed that phosphorylated Bad in-
creased in tubular epithelial cells in HGF-treated kidney,
suggesting that HGF gene transfer activated Akt-Bad
cascade. The role of Bcl-2 and Bax in the process of apop-
tosis has been widely investigated. It is postulated that
Bcl-2 and Bax are a pair of homologous proteins having
inverse effects on cell growth and cell death. Bcl-2 serves
as an inhibitor of apoptosis, while Bax acts as a proapop-
totic antagonist against the cell survival effect of Bcl-
2. However, there are only limited data regarding Bcl-2
regulation in CsA nephrotoxicity. Our data showed that
Bcl-2 is diminished in CsA-treated tubular epithelial cells,
while HGF supplementation increased Bcl-2 expression.
Neither CsA nor HGF affected the Bax expression (data
not shown). In current study, we found that HGF treat-
ment directly inhibited caspase-3 activity correlated with
the up-regulation of Bcl-2. Our finding further confirms
that HGF may execute the anti-apoptotic function by en-
hancing the phosphorylation of Akt and Bcl-2.
TGF-b is a fibrotic cytokine and plays an important
role in CsA-induced accumulation of extracellular matrix
protein. The role of TGF-b in mediating CsA nephro-
toxicity has been evaluated in several studies. CsA has
been shown to up-regulate TGF-b expression in murine
tubular cells and tubulointerstitial fibroblasts [27]. In
patients with chronic allograft nephropathy and CsA-
nephrotoxicity, there is increased TGF-b production [28].
Neutralizing TGF-b antibody prevents matrix synthesis
and attenuates renal injury and renal function in CsA
nephrotoxicity [22]. A reciprocal change in the expres-
sion of TGF-b and HGF was noted during the onset of
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tubulointerstitial fibrosis caused by unilateral ureter lig-
ated obstruction in mice [14]. We observed the increase
of plasma HGF by CsA treatment (1.25 ± 0.14 ng/mL and
1.23 ± 0.08 ng/mL at 2 and 3 weeks, respectively). How-
ever, continuous renal tissue injury and persistent expres-
sion of TGF-b may lead decrease of endogenous HGF
and result in irreversible renal insufficiency. In this study,
HGF gene transfer attained further up-rise of plasma
HGF level (1.69 ± 0.08 ng/mL and 1.59 ± 0.32 ng/mL
at 2 and 3 weeks, respectively) that indicated to play
several roles against renal damage beyond physiological
level. In addition, HGF gene transfer decreased TGF-
b mRNA levels in CsA-treated kidney. HGF prevents
epithelial cell death and remodeling of renal tissue with
injury or fibrosis, which is completely opposite role of
TGF-b . Therefore, exogenous HGF supplement could
be a therapeutic target against renal injury. In fact, sev-
eral studies demonstrate that HGF has preventive and
therapeutic effects in cases of acute and chronic renal
failure/renal fibrosis in laboratory animals. It is unclear
whether HGF suppresses TGF-b expression directly or
indirectly, but the supplement of HGF results in suppres-
sion of TGF-b expression and enhances remodeling of
renal tissues. These results support the hypothesis that
the counterbalance between TGF-b and HGF has de-
terminant role in the pathogenesis and therapeutics of a
fibrosis related diseases.
We used gene transfer approach instead of recom-
binant protein for the following reasons. First, since
the half life of HGF is quite short, recombinant HGF
treatment requires a huge dose of recombinant pro-
tein and frequent injections. Second, administered high
dose of HGF protein may cause adverse effects. Finally,
recombinant protein is costly. On the contrary, gene
transfer is simple, safe, cheap, and needs less frequent
injections. Here, we adopted electroporation-mediated
gene transfer into muscle. Recently, gene transfer by elec-
troporation in vivo has been demonstrated to be effective
for introducing DNA into mouse muscle [29]. We also
demonstrated that PDGFR/Fc gene transfer by the elec-
troporation into skeletal muscle resulted in a significant
increase in the protein level [16]. In addition, regener-
ating muscle by treatment with bupivacaine prior to the
transfection produced 80-fold or more increased gene ex-
pression at protein level [30].
CONCLUSION
We demonstrated that HGF gene transfer reduced
CsA-induced tubulointerstitial injury in two ways; pro-
tection of tubular epithelial cells and inhibition of
interstitial fibrosis. It is speculated that electroporation-
mediated HGF gene transfer has value in treating chronic
CsA-induced nephrotoxicity.
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